Danaher Corporation
DHR#77 of 134 by buybacksNYSE · Healthcare · Diagnostics & Research · USA
danaher.comBuybacks · TTM to Jun 2026$2.90Blatest four quarters
Buyback yield1.9%repurchases ÷ market cap
Dividends · TTM to Jun 2026$964Mdividend yield 0.6%
Shareholder yield2.5%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−4.2%708M shares (2026)
Buybacks ÷ free cash flow53%payout incl. dividends 71%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $3.09B | $878M | $5.26B |
| FY2024Dec 2024 | $5.98B | $768M | $5.30B |
| FY2023Dec 2023 | −$1.01B | $821M | $5.78B |
| FY2022Dec 2022 | −$934M | $818M | $7.37B |
| FY2021Dec 2021 | −$3.25B | $742M | $7.06B |
| FY2020Dec 2020 | −$5.70B | $615M | $5.42B |
| FY2019Dec 2019 | −$16.5B | $751M | $3.32B |
Repurchases in FY2025 were −48.4% versus the prior year.
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process li…
- Market cap
- $155B
- P/E (trailing)
- 39.2×
- Fiscal year end
- December
- ISIN
- US2358511028
- Reporting currency
- USD
- Data updated
- Oct 10, 2026